Therapeutic developments in sudden cardiac death

J. J. Goldberger, S. Neelagaru

Research output: Contribution to journalReview articlepeer-review


Sudden cardiac death is characterised by the unexpected death of a patient who has been clinically stable. It is frequently due to the development of ventricular tachyarrhythmias. With appropriate treatment, patients can be appropriately resuscitated. Clinically, it is essential to develop treatment strategies to prevent such an episode, as most patients do not survive out-of-hospital cardiac arrest. β-blockers are an effective pharmacological therapy in patients following myocardial infarction and in those with congestive heart failure. They may also be effective in other types of heart disease. Anti-arrhythmic agents are not useful as prophylactic drug therapy for reducing mortality in patients at risk for sudden cardiac death. Amiodarone is a notable exception, which may have some benefit, particularly in some subgroups. The implantable cardioverter-defibrillator has emerged as the most effective therapy for preventing sudden cardiac death in high-risk patients. Further work is required to enhance the characterisation of high-risk patients. Genetic analyses in patients with cardiovascular disorders may also identify new approaches to the prevention of sudden cardiac death.

Original languageEnglish (US)
Pages (from-to)2543-2554
Number of pages12
JournalExpert opinion on investigational drugs
Issue number11
StatePublished - 2000
Externally publishedYes


  • Anti-arrhythmic drugs
  • Brugada syndrome
  • Implantable cardioverter-defibrillator
  • Long QT syndrome
  • Sudden cardiac death
  • β-blockers

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Therapeutic developments in sudden cardiac death'. Together they form a unique fingerprint.

Cite this